Cassandra Johnson1, Vernon S Pankratz1, Ana I Velazquez1, Jeremiah A Aakre1, Charles L Loprinzi1, Nathan P Staff1, Anthony J Windebank2, Ping Yang1. 1. Departments of Neurology, Oncology, Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN, USA. 2. Departments of Neurology, Oncology, Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN, USA. Electronic address: windebank.anthony@mayo.edu.
Abstract
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity secondary to chemotherapy. Genetic factors may be important in predisposing patients to this adverse effect. PATIENTS AND METHODS: We studied 950 primary lung cancer patients, who received platinum or platinum-combination drug chemotherapy and who had DNA available for study. We analyzed epidemiological risk factors in 279 CIPN patients and 456 non-CIPN patients and genetic risk factors in 141 CIPN patients and 259 non-CIPN patients. The risk factors studied included demographic, diagnostic, and treatment data, as well as 174 tag SNPs (single nucleotide polymorphisms) across 43 candidate genes in the glutathione, cell cycle, DNA repair, cell signaling, and apoptosis pathways. RESULTS: Patients who had diabetes mellitus were more likely to have CIPN (p=0.0002). Other epidemiologic risk factors associated with CIPN included number of cycles (p=0.0004) and type of concurrent chemotherapy (p<0.001). SNPs most associated with CIPN were in glutathione peroxidase 7 (GPX7) gene (p values 0.0015 and 0.0028, unadjusted and adjusted) and in ATP-binding cassette sub-family C member 4 (ABCC4) gene (p values 0.037 and 0.006, unadjusted and adjusted). We also found other suggestive associations in methyl-o-guanine-methyl-transferase (MGMT) and glutathione-S-transferase (GST) isoforms. CONCLUSIONS: Epidemiological and genetic risk factors associated with CIPN in this cohort, included the type of chemotherapy drug, intensity of chemotherapy treatment, and genes known to be associated with chemotherapy resistance. These findings suggest that differentiating between cytotoxic and neurotoxic mechanisms of chemotherapy drugs is challenging but represents an important step toward individualized therapy and improving quality of life for patients.
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity secondary to chemotherapy. Genetic factors may be important in predisposing patients to this adverse effect. PATIENTS AND METHODS: We studied 950 primary lung cancerpatients, who received platinum or platinum-combination drug chemotherapy and who had DNA available for study. We analyzed epidemiological risk factors in 279 CIPN patients and 456 non-CIPNpatients and genetic risk factors in 141 CIPN patients and 259 non-CIPNpatients. The risk factors studied included demographic, diagnostic, and treatment data, as well as 174 tag SNPs (single nucleotide polymorphisms) across 43 candidate genes in the glutathione, cell cycle, DNA repair, cell signaling, and apoptosis pathways. RESULTS:Patients who had diabetes mellitus were more likely to have CIPN (p=0.0002). Other epidemiologic risk factors associated with CIPN included number of cycles (p=0.0004) and type of concurrent chemotherapy (p<0.001). SNPs most associated with CIPN were in glutathione peroxidase 7 (GPX7) gene (p values 0.0015 and 0.0028, unadjusted and adjusted) and in ATP-binding cassette sub-family C member 4 (ABCC4) gene (p values 0.037 and 0.006, unadjusted and adjusted). We also found other suggestive associations in methyl-o-guanine-methyl-transferase (MGMT) and glutathione-S-transferase (GST) isoforms. CONCLUSIONS: Epidemiological and genetic risk factors associated with CIPN in this cohort, included the type of chemotherapy drug, intensity of chemotherapy treatment, and genes known to be associated with chemotherapy resistance. These findings suggest that differentiating between cytotoxic and neurotoxic mechanisms of chemotherapy drugs is challenging but represents an important step toward individualized therapy and improving quality of life for patients.
Authors: Yafei Li; Zhifu Sun; Julie M Cunningham; Marie C Aubry; Jason A Wampfler; Gary A Croghan; Cassandra Johnson; Danli Wu; Jeremiah A Aakre; Julian Molina; Liewei Wang; V Shane Pankratz; Ping Yang Journal: Clin Cancer Res Date: 2011-06-01 Impact factor: 12.531
Authors: Zhifu Sun; Marie-Christine Aubry; Claude Deschamps; Randolph S Marks; Scott H Okuno; Brent A Williams; Hiroshi Sugimura; V Shane Pankratz; Ping Yang Journal: J Thorac Cardiovasc Surg Date: 2006-05 Impact factor: 5.209
Authors: Riad Schulz; Thomas Emmrich; Heidi Lemmerhirt; Ulrike Leffler; Kristin Sydow; Carsten Hirt; Thomas Kiefer; Andreas Link; Patrick J Bednarski Journal: Bioorg Med Chem Lett Date: 2012-09-05 Impact factor: 2.823
Authors: Lauren E Ta; Allan J Bieber; Susan M Carlton; Charles L Loprinzi; Philip A Low; Anthony J Windebank Journal: Mol Pain Date: 2010-03-05 Impact factor: 3.395
Authors: P J Dyck; K M Kratz; J L Karnes; W J Litchy; R Klein; J M Pach; D M Wilson; P C O'Brien; L J Melton; F J Service Journal: Neurology Date: 1993-04 Impact factor: 9.910
Authors: Alexandre Chan; Daniel L Hertz; Manuel Morales; Elizabeth J Adams; Sharon Gordon; Chia Jie Tan; Nathan P Staff; Jayesh Kamath; Jeong Oh; Shivani Shinde; Doreen Pon; Niharkia Dixit; James D'Olimpio; Cristina Dumitrescu; Margherita Gobbo; Kord Kober; Samantha Mayo; Linda Pang; Ishwaria Subbiah; Andreas S Beutler; Katherine B Peters; Charles Loprinzi; Maryam B Lustberg Journal: Support Care Cancer Date: 2019-07-30 Impact factor: 3.603
Authors: Arya Shah; E Matthew Hoffman; Michelle L Mauermann; Charles L Loprinzi; Anthony J Windebank; Christopher J Klein; Nathan P Staff Journal: J Neurol Neurosurg Psychiatry Date: 2018-02-08 Impact factor: 10.154
Authors: Jewel L Podratz; Amit Kulkarni; Josef Pleticha; Rahul Kanwar; Andreas S Beutler; Nathan P Staff; Anthony J Windebank Journal: J Neurol Sci Date: 2015-12-28 Impact factor: 3.181